Inventiva Announces Completion of Stabilization Operations for its US Offering
Inventiva has announced the conclusion of stabilization operations related to its public offering in the United States, involving American Depositary Shares (ADS).
According to the announcement, Inventiva recently launched a public offering in the United States involving 38,961,038 American Depositary Shares (ADS), each ADS representing one ordinary share of the company with a nominal value of 0.01 euros. The bookrunners associated with the operation fully exercised their option to subscribe to an additional 5,844,155 ADSs. The offering price was set at $3.85 per ADS on the Nasdaq Global Market.
Role of Piper Sandler and Stabilization Period
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Inventiva reports that Piper Sandler acted as the stabilization agent for these shares. The stabilization period took place from November 13 to November 17, 2025. During this period, Piper Sandler purchased 20,700 shares at an average price of $3.6933, with a low of $3.58 and a high of $3.72, totaling $76,451.31.
Regulatory Compliance and Publication Obligations
Inventiva clarifies that these operations were carried out in accordance with the European Market Abuse Regulation and the Delegated Regulation. The announcement also serves to fulfill the publication obligations for Piper Sandler. It is emphasized that the document does not constitute an offer or solicitation to purchase securities in any jurisdiction. Furthermore, the securities from the offering are not intended for the general public in France, except for certain qualified investors, and are subject to restrictions in the European Economic Area and the United Kingdom.
Position de trésorerie au 30/09/2025 de 97,6 millions d’euros (plus 24,7 millions d’euros en dépôts à court terme) ; revenus de 4,5 millions d'euros sur les neuf premiers mois de 2025 principalement liés à CTTQ ; flux opérationnels consommés de - 76,3 millions d’euros et flux d'investissement de - 25 millions d’euros ; flux de financement positifs de 103,4 millions d’euros incluant le produit net de la deuxième tranche du financement structuré. Offre publique en novembre 2025 d’ADS apportant un produit net d’environ 139,3 millions d’euros et estimation d’un horizon de trésorerie jusqu’à fin T1 2027 (pouvant aller jusqu’à mi-T3 2027 si exercice intégral de la Tranche 3 pouvant apporter 116,0 millions d'euros).
Risks mentioned
Besoin de capitaux supplémentaires pour financer les opérations
Risque que la Société utilise ses ressources plus rapidement que prévu
Incertitudes et risques liés aux essais cliniques et aux autorisations réglementaires
Dépendance au succès du lanifibranor et des résultats de l'essai NATiV3
Opportunities identified
Produit net de l’offre publique en novembre 2025 d’environ 139,3 millions d’euros renforçant la trésorerie
Exercice potentiel de la Tranche 3 pouvant apporter jusqu’à 116,0 millions d'euros supplémentaires
Paiement d'étape et avoirs liés à l’accord avec CTTQ (10 M$ et 5 M$)
Résultats principaux de l’essai NATiV3 attendus au second semestre 2026
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
